For the quarter ending 2025-09-30, IONS made $156,719K in revenue. -$128,606K in net income. Net profit margin of -82.06%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 156,719 | 452,049 | - | 133,814 |
| Cost of sales | 2,338 | 4,151 | - | 1,071 |
| Research, development and patent | 217,754 | 217,460 | - | 219,761 |
| Selling, general and administrative | 96,809 | 90,622 | - | 61,638 |
| Total operating expenses | 316,901 | 312,233 | - | 282,470 |
| Loss from operations | -160,182 | 139,816 | -146,860 | -148,656 |
| Investment income | 23,682 | 24,687 | 24,667 | 26,228 |
| Interest expense | 4,212 | 4,114 | 4,108 | 4,161 |
| Interest expense related to sale of future royalties | 17,952 | 18,648 | 18,822 | 18,533 |
| Gain (loss) on investments, net | 29,908 | -18,312 | -2,164 | 879 |
| Other income, net | 363 | 102 | 465 | 142 |
| Loss before income tax benefit (expense) | -128,393 | 123,531 | -146,822 | -144,101 |
| Income tax benefit (expense) | 213 | -20 | 116 | -3,621 |
| Net loss | -128,606 | 123,551 | -146,938 | -140,480 |
| Basic net loss per share (in dollars per share) | -0.8 | 0.78 | -0.93 | -0.95 |
| Diluted net loss per share (in dollars per share) | -0.8 | 0.7 | -0.93 | -0.95 |
| Shares used in computing basic net loss per share (in shares) | 159,765,000 | 159,137,000 | 158,735,000 | 148,593,000 |
| Shares used in computing diluted net loss per share (in shares) | 159,765,000 | 182,331,000 | 158,735,000 | 148,593,000 |
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)